JPMorgan Chase & Co. Acquires 561,310 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

JPMorgan Chase & Co. increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 272.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 767,265 shares of the biotechnology company’s stock after buying an additional 561,310 shares during the period. JPMorgan Chase & Co. owned about 0.32% of ADMA Biologics worth $13,159,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI bought a new position in ADMA Biologics in the third quarter worth about $35,000. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at about $35,000. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics during the fourth quarter valued at about $51,000. Finally, AlphaQuest LLC bought a new stake in shares of ADMA Biologics in the 4th quarter valued at about $84,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Up 3.9 %

ADMA Biologics stock opened at $19.40 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market cap of $4.59 billion, a PE ratio of 69.29 and a beta of 0.53. The stock has a 50-day moving average of $17.78 and a two-hundred day moving average of $18.16. ADMA Biologics, Inc. has a one year low of $5.91 and a one year high of $23.64.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.